A QBD Approach Based RP-HPLC Method Development and Validation for Simultaneous Estimation of Dapagliflozin Propanediol Monohydrate and Sacubitril-Valsartan Sodium Complex Salt in Its Synthetic Mixture

A robust, sensitive, and reproducible reverse-phase high-performance liquid chromatography (RP-HPLC) method was developed and validated using a Quality by Design (QbD) approach for the simultaneous estimation of dapagliflozin propanediol monohydrate and sacubitril–valsartan sodium complex in a synthetic mixture. Critical method parameters were systematically optimized through experimental design to ensure optimal separation, peak symmetry, and resolution. The chromatographic separation was achieved using a suitable C18 column with an optimized mobile phase composition under isocratic conditions. The method demonstrated excellent linearity, precision, accuracy, and specificity within the tested concentration ranges. Validation was performed in accordance with regulatory guidelines, confirming the reliability of the method for routine analysis. The QbD framework enabled a thorough understanding of method variability and robustness, ensuring consistent performance. This developed method can be effectively applied for quality control and simultaneous quantification of these drugs in combined pharmaceutical formulations.

Quality by Design (QbD), RP-HPLC, Dapagliflozin

1. Reddy PKC, Mathur P. QbD driven analytical method development and validation of metformin and dapagliflozin by RP-HPLC. International Journal of Health Sciences. 2022;6(S2):12345–12352. [Google Scholar] [Crossref]

2. Kadam GM, Puyad AL, Kalyankar TM. RP-HPLC method development and validation for estimation of sacubitril and valsartan in pharmaceutical dosage form. Research Journal of Pharmacy and Technology. 2021;14(11):6032–6038 [Google Scholar] [Crossref]

3. Alluri NR, Bandlamudi MR, Kuppusamy S, et al. Implementation of quality by design approach to analytical method development and validation by RP-HPLC. ACS Omega. 2025;10(5):1234–1245. [Google Scholar] [Crossref]

4. Mandhare S, Godge R, Vikhe A, et al. Development and validation of a QbD-based RP-HPLC method: a lifecycle approach. Journal of Applied Pharmaceutical Research. 2024;12(2):1–10. [Google Scholar] [Crossref]

5. Sebaiy MM, El-Adl SM, Baraka MM, Hassan WS. Quality by design approach for development and validation of RP-HPLC method for simultaneous estimation of xipamide and valsartan. BMC Chemistry. 2022;16(1):1–14.\ [Google Scholar] [Crossref]

6. Kasichayanula S, et al., Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, Clinical Pharmacokinetics, 2014; 53(1): 17–27. [Google Scholar] [Crossref]

7. McMurray JJV, et al., Angiotensin–neprilysin inhibition versus enalapril in heart failure, New England Journal of Medicine, 2014; 371: 993–1004. [Google Scholar] [Crossref]

8. Drug Profile for Dapagliflozin Propanediol Monohydrate 2021, https://go.drugbank.com/salts/DBSALT001101 https://pubchem.ncbi.nlm.nih.gov/compound/Dapagliflozin-Propanediol [Google Scholar] [Crossref]

9. Drug profile for sacubitril” https://go.drugbank.com/drugs/DB09292#:~:text=Sacubitril%20is%20a%20neprilysi n%20inhibitor, IV) %20and%20reduced%20ejection%20fraction. (Cited Aug 2025) [Google Scholar] [Crossref]

10. “Drug profile for valsartan” https://go.drugbank.com/drugs/DB00177 [Google Scholar] [Crossref]

• From Policy to Practice: A Qualitative Exploration of Stakeholders’ Awareness and Experiences with the Implementation of the Zero-Tariff Executive Order on Critical Pharmaceutical Inputs